It's pretty crazy that Chip Clark would even suggest anyone should spend $150mm on GEN-003 — a subunit vaccine (which the late Prof. Halford explained is unlikely to move the needle on HSV treatment due to lack of antigenic breadth) — instead of spending $20mm on AuRx — a live-attenuated (IIRC) vaccine which has proven more effective than GEN-003 in Phase II trials.

https://www.researchgate.net/publication/262422871_Antigenic...